Deleted Tweets From Scott Gottlieb, R-D.C.

RT @US_FDA: YUMA UPDATE: #FDA recently met with the Leafy Greens Food Safety Task Force related to the romaine E. coli outbreak… https://t.co/5yC2m0eBBw

5/5 We’re committed to doing our part to expand access to high-quality, effective MAT. This work also includes improving understanding about the treatment options available for patients and countering the unfortunate stigma that’s sometimes associated with their use.

4/5 Today’s action builds on another draft guidance issued in April regarding drug development and trial design issues relevant to the study of depot buprenorphine products (i.e., modified-release products for injection or implantation) for OUD: https://t.co/onLB1n57PH

RT @FDAMedia: FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder https://t.co/MFSTzv9iyr

RT @RAPSorg: CDER Director Janet Woodcock spoke with #Regulatory Focus' @ZacharyBrennan Friday about CDER's reorganization,… https://t.co/wXqrIEkrHr

THREAD: #FDA is highly supportive of the development of abuse-deterrent formulations (ADFs) of opioid products, but we evaluate ADFs on a product-specific basis to ensure their benefits outweigh their risks https://t.co/yvxExIz7vy

The science of abuse deterrence is relatively new and rapidly evolving, and we continue to study the role of ADFs in the real world to reduce opioid misuse and abuse via different routes

We’ll take other new steps soon to encourage ADF development. #FDA’s goal is to decrease the rate of new addiction and to make misuse and abuse of opioids more difficult. ADFs play a promising role in this objective. We’ll continue to support development of ADF products

While we’ve seen discreet issues with certain products impacting their ability to meet our approval threshold, these situations don’t reflect any change to our commitment to ADFs and their potential value to combatting misuse and abuse. We strongly support ADF development.

#FDA recently issued several product-specific guidances for development of generic ADF opioids as part of our work to encourage access and adoption; and enable drug developers to also bring safe, effective and high-quality generic products to market https://t.co/yvxExIz7vy

RT @FDA_ORA: Have you heard of FDA’s “American Chamber of Horrors?” This traveling exhibit highlighted around 100 dangerous, dec… https://t.co/t5npdSDa47

RT @FDAJobs: Interested in a career at the FDA? Check out https://t.co/5aAx7r3Gdm

ORGANIC FACTS: In coming weeks I'm going to put out more detailed information on what different terms mean on food packaging, to help consumers best use claims like organic, antibiotic free, etc. Since these issues are in the news today, I wanted to offer a few initial thoughts:

#FDA and USDA have distinct roles when it comes to the oversight of organic foods. USDA is charged with regulating use of the term “organic” on food labels whereas FDA oversees general food labeling compliance and safety issues: https://t.co/8jQaXeMDWa

Together, both #FDA and USDA help ensure the safety of the foods people eat, including organic foods, while also providing consumers access to factual information in a product’s label about how a food was produced: https://t.co/gDbIh3m0k7

#FDA is focused on empowering consumers with tools and information to make good food choices consistent with public health recommendations, and encourage development of healthier foods by industry. This also means making sure terms on labels are actionable https://t.co/ueLbo3ZtQE

Check out the new ad from @FDATobacco’s multicultural youth campaign, “Fresh Empire,” which focuses on empowering teens to live tobacco-free: https://t.co/WQvjzfssHO and learn more about #FDA’s public education campaigns here: https://t.co/iwH7HLUCM8

THREAD: 1/2 At #BSidesLV, #FDA will be talking about coordinated vulnerability disclosures, including plans from our Medical Device Safety Action Plan for a CyberMed Safety Analysis Board, a public-private entity with experts from govt, academia & industry https://t.co/QzkGalnJNW

2/2: #FDA CyberMed Safety Analysis Board would bring together a broad range of requisite expertise in areas such as hardware, software, networking, biomedical engineering, and clinical expertise to fully assess and validate high-risk medical device vulnerabilities and incidents

RT @repgregwalden: Thank you to local law enforcement and medical providers for joining today’s roundtable with @SGottliebFDA to discuss ef… QT @SGottliebFDA: Grateful for opportunity to join @repgregwalden in Bend, OR today to discuss the opioid crisis with a group of loca… https://t.co/umjbs8Ja1B)

RT @US_FDA: YUMA UPDATE: #FDA recently met with the Leafy Greens Food Safety Task Force related to the romaine E. coli outbreak… https://t.co/5yC2m0eBBw

5/5 We’re committed to doing our part to expand access to high-quality, effective MAT. This work also includes improving understanding about the treatment options available for patients and countering the unfortunate stigma that’s sometimes associated with their use.

4/5 Today’s action builds on another draft guidance issued in April regarding drug development and trial design issues relevant to the study of depot buprenorphine products (i.e., modified-release products for injection or implantation) for OUD: https://t.co/onLB1n57PH

RT @FDAMedia: FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder https://t.co/MFSTzv9iyr

RT @RAPSorg: CDER Director Janet Woodcock spoke with #Regulatory Focus' @ZacharyBrennan Friday about CDER's reorganization,… https://t.co/wXqrIEkrHr

THREAD: #FDA is highly supportive of the development of abuse-deterrent formulations (ADFs) of opioid products, but we evaluate ADFs on a product-specific basis to ensure their benefits outweigh their risks https://t.co/yvxExIz7vy

The science of abuse deterrence is relatively new and rapidly evolving, and we continue to study the role of ADFs in the real world to reduce opioid misuse and abuse via different routes

We’ll take other new steps soon to encourage ADF development. #FDA’s goal is to decrease the rate of new addiction and to make misuse and abuse of opioids more difficult. ADFs play a promising role in this objective. We’ll continue to support development of ADF products

While we’ve seen discreet issues with certain products impacting their ability to meet our approval threshold, these situations don’t reflect any change to our commitment to ADFs and their potential value to combatting misuse and abuse. We strongly support ADF development.

#FDA recently issued several product-specific guidances for development of generic ADF opioids as part of our work to encourage access and adoption; and enable drug developers to also bring safe, effective and high-quality generic products to market https://t.co/yvxExIz7vy

RT @FDA_ORA: Have you heard of FDA’s “American Chamber of Horrors?” This traveling exhibit highlighted around 100 dangerous, dec… https://t.co/t5npdSDa47

RT @FDAJobs: Interested in a career at the FDA? Check out https://t.co/5aAx7r3Gdm

ORGANIC FACTS: In coming weeks I'm going to put out more detailed information on what different terms mean on food packaging, to help consumers best use claims like organic, antibiotic free, etc. Since these issues are in the news today, I wanted to offer a few initial thoughts:

#FDA and USDA have distinct roles when it comes to the oversight of organic foods. USDA is charged with regulating use of the term “organic” on food labels whereas FDA oversees general food labeling compliance and safety issues: https://t.co/8jQaXeMDWa

Together, both #FDA and USDA help ensure the safety of the foods people eat, including organic foods, while also providing consumers access to factual information in a product’s label about how a food was produced: https://t.co/gDbIh3m0k7

#FDA is focused on empowering consumers with tools and information to make good food choices consistent with public health recommendations, and encourage development of healthier foods by industry. This also means making sure terms on labels are actionable https://t.co/ueLbo3ZtQE

Check out the new ad from @FDATobacco’s multicultural youth campaign, “Fresh Empire,” which focuses on empowering teens to live tobacco-free: https://t.co/WQvjzfssHO and learn more about #FDA’s public education campaigns here: https://t.co/iwH7HLUCM8

THREAD: 1/2 At #BSidesLV, #FDA will be talking about coordinated vulnerability disclosures, including plans from our Medical Device Safety Action Plan for a CyberMed Safety Analysis Board, a public-private entity with experts from govt, academia & industry https://t.co/QzkGalnJNW

2/2: #FDA CyberMed Safety Analysis Board would bring together a broad range of requisite expertise in areas such as hardware, software, networking, biomedical engineering, and clinical expertise to fully assess and validate high-risk medical device vulnerabilities and incidents

RT @repgregwalden: Thank you to local law enforcement and medical providers for joining today’s roundtable with @SGottliebFDA to discuss ef… QT @SGottliebFDA: Grateful for opportunity to join @repgregwalden in Bend, OR today to discuss the opioid crisis with a group of loca… https://t.co/umjbs8Ja1B)